Global Regulatory Monitor
Regulatory News, Week 3 · 2026/10

Residue found inside equipment already released as clean suggests that inspectors may probe whether post-cleaning visual checks reach hidden sections of process equipment. Firms sourcing pellets or other intermediates from overseas sites may need to review the EU GMP status and supply continuity of those sites.

This signals that FDA has finalized its position on managing postapproval manufacturing changes for biosimilars. Detailed requirements should be confirmed in the source document, and holders of such products may need to compare it with their change control procedures.

Findings spanning OOS investigation, airflow pattern testing and freeze-dryer hold times can be read as a signal that the sufficiency of investigation rationale and equipment qualification data was the inspection focus. Sites operating freeze-dryers should check that the rationale for hold times between sterilization cycles is documented.

Findings combining filter validation, media fill and settle plate monitoring can be read as a signal that the sufficiency of validation and environmental data explanations was the inspection focus. Because revalidation and sampling methods were explicitly cited for cleaning validation, sites should check the rationale for revalidation frequency and sampling methods.

Findings on contractor oversight, operator disinfection and manual cleaning can be read as a signal that evidence for people-dependent procedures was examined. Sites using manually cleaned equipment should check whether their cleaning effectiveness evidence accounts for operator-to-operator variation.

Findings combining equipment performance qualification, process validation and drug substance input quantity can be read as a signal that the link between process set points and supporting evidence was the inspection focus. Sites making both finished products and drug substance should check that the rationale for input quantity matches process validation results.

Issuing a certificate one day before the sterility result was finalized can be seen as a data integrity issue in which documents were released ahead of confirmed results. Importers relying on underlying certificates should check that their own certificate issue dates never precede the final judgment dates of those certificates.

Failures on two different test items across two products can be read as a signal about overall pre-release testing control rather than a single test. Sulfur dioxide residue can generally be associated with processing history at raw material receipt, so receipt testing and release testing criteria should be checked together.

A suspension based solely on the origin labeling format can be seen as showing that herbal material labeling form itself is enforceable. Labeling reviews for herbal materials should check that origin statements include every element the regulation requires.

Switching the active ingredient supplier without a licence change can be seen as a supplier change that never reached change control or regulatory filing. Because shipments without release approval were also cited, medical gas sites should check that supplier changes and release approval are linked in their documentation.

Detection of unremoved rootlets and bark in market sampling can be seen as pre-release appearance checks failing to screen non-medicinal parts. This can generally be associated with cleaning and sorting control, so manufacturers should check that release appearance criteria explicitly cover removal of rootlets and outer bark.

The combination of a missing import manager and skipped quality testing can be seen as a breakdown of pre-release quality accountability for imported products. Importers should check that manager appointments and registered details such as location match actual operations.

Issuing a warning for 50 late reports can be seen as showing that system reporting is enforced as a per-transaction deadline obligation. Narcotics manufacturers should periodically reconcile the timing of manufacturing and sales events against system reporting.

A sales suspension for missing the report deadline can be seen as a signal that risk management plan timelines directly affect a product's ability to stay on the market. Companies holding RMP products should check that surveillance end dates and report deadlines are tracked per product.

A product-level fine based only on an unreported storage site can be seen as showing that storage locations are bound to the reported facility scope. Importers should check that every actual storage location, including temporary ones, matches their facility notification.

Three herbal products from one supplier being recalled together for cadmium failure shows that heavy metal control remains a recurring recall reason for herbal materials. Heavy metal failures can generally be linked to cultivation conditions, so heavy metal testing at receipt may need review.

An appearance failure is a deviation in basic identification attributes, suggesting a need to check how effective organoleptic inspection at receipt is. Such failures can generally be linked to origin mix-ups or deterioration in storage, so identification criteria and storage conditions may need review.

Dissolution-failing product reaching the market suggests a need to check whether release testing or stability monitoring failed to catch the issue. Dissolution shifts can generally be linked to formulation or process conditions, so dissolution trending for tablet products may need review.

A mandatory recall for sulfur dioxide suggests residual sulfur dioxide in herbal materials remains an ongoing regulatory focus. Sulfur dioxide residues can generally be linked to drying or storage steps, so oversight of herbal processors and receipt testing may need review.

A recall triggered solely by an importer address error, not product quality, suggests that labeling particulars can directly lead to recalls. Firms handling imported drugs may need to check that label revisions are not missed when company details such as addresses change.

This is a recall driven by a distribution error rather than a quality defect, signalling that shipping control gaps alone can trigger a recall. Companies using contract distribution may need to check reconciliation between shipping orders and actual deliveries.

An allergy tablet product was recalled from wholesalers over a distribution error, signalling that shipping control issues unrelated to quality can still trigger recalls. Companies shipping to multiple wholesalers may need to check traceability of shipment records per wholesaler.

This signals that natural health products can also be recalled from wholesale over a distribution error alone. Companies shipping both drugs and health products may need to check that shipping controls apply consistently across product categories.

Because the risk was found in routine stability investigations rather than at release, this can be seen as a case of the stability programme catching changes during storage. Sites handling infusion products may need to review particulate assessment of stability samples and impact assessment on marketed batches.

Low dissolution in an extended-release tablet can signal that the release profile is not being maintained as designed. Holders of extended-release products may need to review dissolution trends, including changes over the stability period.

Shipping empty or underfilled packets suggests that fill weight control or packaging inspection did not catch the defect. Holders of unit-dose packaged products may need to review fill checks and reject functions.

A finding of lack of sterility assurance for a product labeled sterile can signal doubts about the overall sterility assurance system. Holders of sterile products may need to check that sterility assurance evidence is adequately tied to batch release decisions.

Prolonged uncontrolled exposure in a carrier trailer led to a recall, signalling that temperature control must extend to contracted carriers. Companies using contract transport may need to review in-transit temperature monitoring and handling of delays.

Crystallization in an injection signals that the physical stability of the solution was not maintained. Since crystallization can generally be associated with storage temperature or formulation, holders of solution injections may need to review visual inspection and stability criteria for precipitation.

A dissolution failure in an extended-release tablet signals that release control fell outside approved limits. Holders of extended-release products may need to review the scope of dissolution OOS investigations and impact assessment on other batches.

Two products recalled together for microbial contamination may signal a broader microbial control issue, which can generally be associated with shared equipment or process water. Holders of non-sterile topical products may need to review microbial limit testing and hygiene of shared equipment.